Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
16-30 of 474
Emerging Biomarker Research for NSCLC Antibody-Drug Conjugates
Project Oncology®Emerging Biomarker Research for NSCLC Antibody-Drug Conjugates
Christine Bestvina, MD
The Importance of Multidisciplinary Coordination in NSCLC Care
Project Oncology®The Importance of Multidisciplinary Coordination in NSCLC Care
Laura Alder, MD
Innovations Shaping the Future of Antibody-Drug Conjugates in NSCLC
Project Oncology®Innovations Shaping the Future of Antibody-Drug Conjugates in NSCLC
Christine Bestvina, MD
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Project Oncology®Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Alexandria May, PharmD, BCPS
Shannon Raber, MS, CPNP, RN
Bridget Archambault, MSN, CPNP
Managing Antibody-Drug Conjugate Toxicities in NSCLC Care
Project Oncology®Managing Antibody-Drug Conjugate Toxicities in NSCLC Care
Laura Alder, MD
Tobacco-Related Stigma as a Barrier to Lung Cancer Screening
Project Oncology®Tobacco-Related Stigma as a Barrier to Lung Cancer Screening
Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
- advertisement
A New Era of Hope in Non-Small Cell Lung Cancer Care
Project Oncology®A New Era of Hope in Non-Small Cell Lung Cancer Care
Geoffrey Oxnard, MD
Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Project Oncology®Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Laura Alder, MD
Improving Adherence and Toxicity Monitoring in NSCLC Care
Project Oncology®Improving Adherence and Toxicity Monitoring in NSCLC Care
Raghava Reddy Induru, MD
The Evolving Role of Antibody-Drug Conjugates in NSCLC Care
Project Oncology®The Evolving Role of Antibody-Drug Conjugates in NSCLC Care
Raghava Reddy Induru, MD
Integrating Molecular Testing into NSCLC Care
Project Oncology®Integrating Molecular Testing into NSCLC Care
Geoffrey Oxnard, MD
Smarter Screening for Non-Small Cell Lung Cancer
Project Oncology®Smarter Screening for Non-Small Cell Lung Cancer
Jobelle Baldonado, MD
- advertisement
A Patient-First Approach to Smoking Cessation and Lung Cancer Screening
Project Oncology®A Patient-First Approach to Smoking Cessation and Lung Cancer Screening
Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
Key Questions Shaping Antibody-Drug Conjugate Use in NSCLC
Project Oncology®Key Questions Shaping Antibody-Drug Conjugate Use in NSCLC
Laura Alder, MD
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Project Oncology®Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Geoffrey Oxnard, MD